Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indicatio...
主要な著者: | Sergey Shityakov, Ekaterina V. Skorb, Carola Y. Förster, Thomas Dandekar |
---|---|
フォーマット: | 論文 |
言語: | English |
出版事項: |
Frontiers Media S.A.
2021-10-01
|
シリーズ: | Frontiers in Chemistry |
主題: | |
オンライン・アクセス: | https://www.frontiersin.org/articles/10.3389/fchem.2021.736509/full |
類似資料
-
In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
著者:: Ridwan Abiodun Salaam, 等
出版事項: (2025-03-01) -
A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2
著者:: Madhura Punekar, 等
出版事項: (2022-09-01) -
Editorial: Adopting drug repurposing to overcome drug resistance in cancer
著者:: Eswar Shankar, 等
出版事項: (2023-04-01) -
Network-based drug repurposing for potential stroke therapy
著者:: Qihui Wu, 等
出版事項: (2023-01-01) -
Approved drugs successfully repurposed against Leishmania based on machine learning predictions
著者:: Rafeh Oualha, 等
出版事項: (2024-09-01)